Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2005
05/12/2005US20050100609 Phase-separated polymer coatings
05/12/2005US20050100608 solid dosage; alleviate many of the undesirable consequences of undergoing testosterone therapy, such as the pain of injections and problems with patient noncompliance
05/12/2005US20050100607 administering polyethylene glycol or ethylene oxide-propylene oxide copolymers, with drugs, to improve delivery in the alimentary canal
05/12/2005US20050100606 Controlled release formulation of tamsulosin hydrochloride and preparation process thereof
05/12/2005US20050100605 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
05/12/2005US20050100604 such as in microsphere form that enables easy recovery of the solid sustained-release preparation without environmental exposure for a long time; in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material
05/12/2005US20050100603 Sustained release pharmaceutical composition
05/12/2005US20050100602 Sustained release pharmaceutical composition
05/12/2005US20050100601 Virucidal activities of cetylpyridinium chloride
05/12/2005US20050100600 Pharmaceutical superdisintegrant
05/12/2005US20050100599 Quick disintegrating tablet in buccal cavity and manufacturing method thereof
05/12/2005US20050100598 Quick disintegrating tablet in buccal cavity and production process thereof
05/12/2005US20050100597 salt of diclofenac with tromethamine; gingivitis, glossitis, stomatitis, aphthae, paradentosis, paradentitis, laryngitis, pharyngitis, mucositis of the oral cavity caused by radiotherapy and chemotherapy
05/12/2005US20050100595 Using a set of solutions including an aqueous solution; achieving 100% bioavailability of drugs such as paclitaxel; preparations can be free of polymer carriers and surfactants
05/12/2005US20050100594 Tizanidine and valdecoxib for example; muscle relaxant is released in an extended release manner and a cyclooxygenase-2 inhibitor in immediate release form; treating pain, spasticity
05/12/2005US20050100593 Of gelatin and polyglutamic acid; inhibits an insolubilization phenomenon in the film that occurs during storage of the gelatin capsule; improves bioavailability of mineral ingredients such as calcium or iron
05/12/2005US20050100591 Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
05/12/2005US20050100590 Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumours
05/12/2005US20050100589 Transdermal administration of ace inhibitors
05/12/2005US20050100588 Patch for controlled delivery of active ingredients to the skin comprising a polyurethane gel matrix of active ingredient(s) and penetration enhancer(s)
05/12/2005US20050100587 Topical analgesic and methods of use
05/12/2005US20050100586 drug delivery patches comprising polyester supports, self-adhesive acrylic copolymer matrix layers containing adjuvants, steroids and solvents, and detachable protective layers; drug delivery
05/12/2005US20050100585 Delivery system for topical medications
05/12/2005US20050100566 Water soluble polymer such as carrageenan with self-shape retainability for use as a topical agent when it has a predetermined water content and a compressive deformation ratio; high adaptability to human skins, high strength; cooling gel for example
05/12/2005US20050100564 Controlled release delivery system for nasal applications
05/12/2005US20050100561 Copper silicate; fungal infection
05/12/2005US20050100560 Ethanolamine is oxidation hair dye; hexenol to aid fragrance
05/12/2005US20050100555 Synovial tissue binding peptide; amino acid sequence motifs; identify binding peptides by grafting tissue of first species into second having attenuated immunological response
05/12/2005US20050100530 Medicinal composition
05/12/2005US20050100527 Liposomes for transfection of nucleic acids
05/12/2005US20050100513 Homeopathic method and system for treating nicotine addiction
05/12/2005DE10045343B4 Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels Use of an aqueous solution or suspension for healing of the corneal epithelium
05/12/2005CA2558306A1 Three-dimensional mammalian ovarian follicular cell and ovarian follicle culture systems in a biocompatible matrix
05/12/2005CA2546691A1 Once-a-day, oral, controlled-release, oxycodone dosage forms
05/12/2005CA2544307A1 Pharmaceutical compositions with synchronized solubilizer release
05/12/2005CA2544302A1 Antimicrobial shampoo compositions
05/12/2005CA2544049A1 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof
05/12/2005CA2543945A1 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
05/12/2005CA2543716A1 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
05/12/2005CA2543709A1 Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate
05/12/2005CA2543689A1 Pharmaceutical actve-ingredient-containing formulation with coating
05/12/2005CA2543534A1 Method for transdermal delivery of permeant substances
05/12/2005CA2543496A1 Antimicrobial composites, films, labelstocks and labels
05/12/2005CA2543458A1 Process for co-spray drying agents with dry silicified mcc
05/12/2005CA2543292A1 Reduction of unintended use of transdermal devices
05/12/2005CA2543245A1 Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aqueous vehicle
05/12/2005CA2543242A1 Controlled release sterile injectable aripiprazole formulation and method
05/12/2005CA2543238A1 Compositions and dosage forms for enhanced absorption
05/12/2005CA2543227A1 Administration of levodopa and carbidopa
05/12/2005CA2543198A1 Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
05/12/2005CA2543187A1 Medicamentously targeted local lipolysis
05/12/2005CA2543185A1 Compositions and dosage forms for ehnanced absorption of iron
05/12/2005CA2543181A1 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
05/12/2005CA2543177A1 Compositions and dosage forms for enhanced absorption of metformin
05/12/2005CA2543170A1 Compositions and methods for increasing hdl and hdl-2b levels
05/12/2005CA2543135A1 Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
05/12/2005CA2543086A1 Pretreatment method and system for enhancing transdermal drug delivery
05/12/2005CA2543084A1 Apparatus and method for enhancing transdermal drug delivery
05/12/2005CA2542836A1 Pharmaceutical formulations containing quetiapine
05/12/2005CA2542537A1 Process for producing injectable gabapentin compositions
05/12/2005CA2542530A1 Pharmaceutical aerosol compositions
05/12/2005CA2541445A1 Nanoparticles for drug delivery
05/12/2005CA2540869A1 Spill resistant formulations containing clays
05/12/2005CA2539817A1 Tocopheryl polyethylene glycol succinate articles and process for preparing tpgs articles
05/12/2005CA2535036A1 Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
05/12/2005CA2534236A1 Lipoparticles comprising proteins, methods of making, and using the same
05/12/2005CA2527495A1 High molecular weight polymers, devices and method for making and using same
05/11/2005EP1529536A1 Immunogenic composition having improved immunostimulation capacity
05/11/2005EP1529526A1 Sustained-release pharmaceutical compositon
05/11/2005EP1529524A1 Softgelatine capsule comprising fat-soluble vitamins and essential fatty acids
05/11/2005EP1528940A2 Controlled release device and method
05/11/2005EP1528937A2 Nanoemulsion vaccines
05/11/2005EP1528933A2 Pharmaceutical anti-tnf-alpha antibody formulation
05/11/2005EP1528930A1 Pharmaceutically active substance preparations and drugs that are capable of generating thrombin and/or that contain thrombin
05/11/2005EP1528926A1 Novel pharmaceutical composition of ceftiofur
05/11/2005EP1528918A1 Skin friendly active ingredient plaster based on sbc, containing at least 34 wt % of a pharmaceutical active ingredient and production thereof
05/11/2005EP1528917A2 Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
05/11/2005EP1528916A1 Multicomponent pharmaceutical dosage form
05/11/2005EP1528915A2 Liposomal vaccine
05/11/2005EP1528914A1 Antigenic compositions
05/11/2005EP1528913A1 Coating suspensions (comprising osmopolymers, osmagents) for forming an expandable osmotic composition in controlled release dosage forms as well as the corresponding method for providing this osmotic coating
05/11/2005EP1434571B1 Particle immobilized coatings and uses thereof
05/11/2005EP1417172A4 Process for the preparation of amorphous form of torsemide
05/11/2005EP1399127B1 Olopatadine formulations for topical administration
05/11/2005EP1370245B1 Method to prepare microparticles containing metoprolol
05/11/2005EP1335715B1 Skin-friendly and drug-containing patches for transdermal administration of hyperemic active ingredients
05/11/2005EP1330266B1 Method for making very fine particles consisting of a principle inserted in a host molecule
05/11/2005EP1315480B1 "slow release" pharmaceutical compositions comprising lithium carbonate
05/11/2005EP1313455B1 Controlled and sustained release properties of polyelectrolyte multilayer capsules
05/11/2005EP1165017B1 Liquid dispersion polymer compositions, their preparation and their use
05/11/2005EP1117382B1 Spray coated microparticles for use in needleless syringes
05/11/2005EP1100771B1 Compounds and compositions for delivering active agents
05/11/2005EP1083931B1 Stabilization of compositions containing ace inhibitors using magnesium oxide
05/11/2005EP0986408B1 New medicaments based on polymers composed of methacrylamide-modified gelatin
05/11/2005EP0969815B1 Pharmaceutical compositions
05/11/2005EP0942716B1 Composition for transdermal delivery of drugs
05/11/2005CN2698345Y Mango containing cough-relieving capsule
05/11/2005CN2698344Y Medical pain easing plaster
05/11/2005CN2698340Y Moxibustion plaster
05/11/2005CN1615339A Method for preparing gels
1 ... 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 ... 2991